Professional Summary »
Specializing In »
Practice Locations »
Patient Ratings »
Referring Physicians »
Professional Summary
Education & Certifications
- Medical Education: Medizinische Hochschule Hannover (1996) Germany
- Residency: Albert Einstein College of Medicine (2002) NY
- Fellowship: Memorial Sloan-Kettering Cancer Center (2004) NY
- Fellowship: Stanford University Medical Center (2005) CA
- Board Certification: American Board of Internal Medicine, Hematology (2005)
Awards & Memberships
- Fellowship Award, Lymphoma Research Foundation (2004)
- Methods in Clinical Cancer Research Scholar, ASCO/AACR (2005)
- Research grant, Hope Street Kids Foundation (2006)
- Translational Research Award, Doris Duke Foundation (2004)
- Translational Research Award, Stanford Department of Medicine (2011)
- Young Investigator Award, ASCO (2008)
Administrative Appointments
- Cancer Center Program Lead, Hematology, Stanford (2019 - Present)
- Co-Director, Stanford Amyloid Center (2010 - Present)
- Medical Director, Stanford Adolescent and Young Adult Program (2015 - Present)
- Member Leukemia Committee, Southwest Oncology Group (2011 - Present)
- Unit Based Medical Director Inpatient Hematology, Stanford (2019 - 2021)
Publications
-
A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV
SELENT, U., RUTER, T., Kohler, E., Liedtke, M., THIELKING, V., Alves, J., … Pingoud, A. (1992). A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV. BIOCHEMISTRY, 31(20), 4808–4815. -
Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population
Liedtke, M., Hamlin, P. A., Moskowitz, C. H., & Zelenetz, A. D. (2006). Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. ANNALS OF ONCOLOGY, 17(6), 909–913. -
Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma
Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., & Medeiros, B. (2008). Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. LEUKEMIA & LYMPHOMA, 49(3), 581–85. -
Therapeutic targeting of MLL
Liedtke, M., & Cleary, M. L. (2009). Therapeutic targeting of MLL. BLOOD, 113(24), 6061–68. -
Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6
Liedtke, M., Ayton, P. M., Somervaille, T. C. P., Smith, K. S., & Cleary, M. L. (2010). Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. BLOOD, 116(1), 63–70. -
Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., … Medeiros, B. C. (2010). Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience. AMERICAN JOURNAL OF HEMATOLOGY, 85(11), 877–81. -
Plasma cell leukemia: concepts and management.
Liedtke, M., & Medeiros, B. C. (2010). Plasma cell leukemia: concepts and management. Expert Review of Hematology, 3(5), 543–49. -
Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., … Coutre, S. E. (2012). Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 97(1), 30–37. -
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., … Medeiros, B. C. (2012). Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. LEUKEMIA, 26(5), 893–901. -
Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2012). Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 31(3), 325–31. -
The Transcription Factor Encyclopedia
Yusuf, D., Butland, S. L., Swanson, M. I., Bolotin, E., Ticoll, A., Cheung, W. A., … Wasserman, W. W. (2012). The Transcription Factor Encyclopedia. GENOME BIOLOGY, 13(3). -
More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis
Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., Schrier, S., … Liedtke, M. (2012). More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 138(5), 509–11. -
Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A., … Advani, A. S. (2012). Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia. AMERICAN JOURNAL OF HEMATOLOGY, 87(10), 957–60. -
Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options.
Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., & Liedtke, M. (2012). Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options. Hematology (Amsterdam, Netherlands). -
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., … Medeiros, B. C. (2013). Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 98(4), 591–96. -
Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S., … Kumar, R. (2013). Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(1), 11–17. -
A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia.
Patel, S., Liedtke, M., Ngo, D., & Medeiros, B. C. (2013). A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia. Leukemia & Lymphoma, 54(10), 2231–35. -
The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis
Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., Lafayette, R., … Liedtke, M. (2013). The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 161(3), 367–72. -
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., … Liedtke, M. (2013). Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica, 98(10), 1593–99. -
AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin
Penchala, S. C., Connelly, S., Wang, Y., Park, M. S., Zhao, L., Baranczak, A., … Alhamadsheh, M. M. (2013). AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(24), 9992–97. -
Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase
Liedtke, M., Pandey, P., Kumar, S., KHARBANDA, S., & Kufe, D. (1998). Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase. ONCOGENE, 17(15), 1889–1892. -
Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., & Liedtke, M. (2012). Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study. BLOOD, 120(21). -
Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2011). Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy. JOURNAL OF CARDIAC FAILURE, 17(8), S45–S46. -
Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis
Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., Arai, S., … Witteles, R. M. (2014). Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. HEART RHYTHM, 11(1), 158–62. -
Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression.
Ohgami, R. S., Sendamarai, A. K., Atwater, S. K., Liedtke, M., Fleming, M. D., Natkunam, Y., & Warnke, R. A. (2014). Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression. American Journal of Surgical Pathology, 38(9), 1298–1304. -
Effects of serum and plasma matrices on multiplex immunoassays.
Rosenberg-Hasson, Y., Hansmann, L., Liedtke, M., Herschmann, I., & Maecker, H. T. (2014). Effects of serum and plasma matrices on multiplex immunoassays. Immunologic Research, 58(2-3), 224–33. -
Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia
Dinner, S., Lee, D., & Liedtke, M. (2014). Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA & LYMPHOMA, 55(8), 1715–24. -
Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia
Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., Gotlib, J., … Medeiros, B. (2014). Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. LEUKEMIA RESEARCH, 38(12), 1441–45. -
Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era.
Davis, M. K., Kale, P., Liedtke, M., Schrier, S., Arai, S., Wheeler, M., … Witteles, R. M. (2015). Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. American Journal of Transplantation , 15(3), 650–58. -
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.
Narayan, R., Garcia, J. S., Percival, M.-E. M., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2016). Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leukemia & Lymphoma, 57(3), 609–15. -
Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma
Hansmann, L., Blum, L., Ju, C.-H., Liedtke, M., Robinson, W. H., & Davis, M. M. (2015). Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma. CANCER IMMUNOLOGY RESEARCH, 3(6), 650–60. -
CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
Iwasaki, M., Liedtke, M., Gentles, A. J., & Cleary, M. L. (2015). CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia. Cell Stem Cell, 17(4), 412–21. -
Multiple Myeloma, Version 2.2016
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., … Kumar, R. (2015). Multiple Myeloma, Version 2.2016. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(11), 1398–1435. -
A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., … Liedtke, M. (2016). A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Haematology, 173(2), 253–59. -
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.
Gertz, M. A., Landau, H., Comenzo, R. L., Seldin, D., Weiss, B., Zonder, J., … Liedtke, M. (2016). First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology , 34(10), 1097–1103. -
Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature.
Leatham, H. W., Novoa, R., Liedtke, M., & Kwong, B. Y. (2016). Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature. Clinical Lymphoma, Myeloma & Leukemia, 16(1), e1–5. -
Identification of Doxorubicin as an Inhibitor of the IRE1a-XBP1 Axis of the Unfolded Protein Response.
Jiang, D., Lynch, C., Medeiros, B. C., Liedtke, M., Bam, R., Tam, A. B., … Koong, A. C. (2016). Identification of Doxorubicin as an Inhibitor of the IRE1a-XBP1 Axis of the Unfolded Protein Response. Scientific Reports, 6, 33353-? -
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., … Advani, A. S. (2016). Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 375(8), 740–53. -
Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines
Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., … Kumar, R. (2016). Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(4), 389–400. -
Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., … Kumar, R. (2017). Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(2), 230-? -
Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
DeAngelo, D. J., George, T. I., Linder, A., Langford, C., Perkins, C., Ma, J., … Gotlib, J. (2017). Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. -
Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).
Tuzovic, M., Kobayashi, Y., Wheeler, M., Barrett, C., Liedtke, M., Lafayette, R., … Witteles, R. (2017). Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry). The American Journal of Cardiology, 120(8), 1381–86. -
Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
Advani, A. S., Li, H., Michaelis, L. C., Medeiros, B. C., Liedtke, M., List, A. F., … Appelbaum, F. R. (2018). Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Leukemia Research, 67, 17–20. -
NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY
Liedtke, M., Comenzo, R., Landau, H., Sanchorawala, V., Weiss, B., Zonder, J., … Gertz, M. (2017). NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 69(11), 825. -
NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous haematological response
Liedtke, M. M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2017). NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous haematological response. EUROPEAN JOURNAL OF HEART FAILURE, 19, 441. -
A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Cohen, A. D., Scott, E. C., Liedtke, M., Kaufman, J. L., Landau, H., Vesole, D. H., … Durie, B. G. M. (2014). A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. BLOOD, 124(21). -
Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016
Maurer, M., Lousada, I., Hanna, M., Ruberg, F., Mohty, D., Dispenzieri, A., … Grogan, M. (2017). Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 24, 165–66. -
Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia
Advani, A. S., Li, H., Michaelis, L. C., Medeiros, B. C., Liedtke, M., List, A. F., … Appelbaum, F. R. (2015). Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia. BLOOD, 126(23). -
The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction.
Liedtke, M., Merlini, G., Landau, H. J., Comenzo, R., Seldin, D. C., Weiss, B. M., … Gertz, M. A. (2015). The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. JOURNAL OF CLINICAL ONCOLOGY, 33(15). -
NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study
Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2016). NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study. EUROPEAN HEART JOURNAL, 37, 220. -
Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow
Hansmann, L., Han, A., Penter, L., Liedtke, M., & Davis, M. M. (2017). Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow. CANCER IMMUNOLOGY RESEARCH, 5(9), 744–54. -
NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Castillo, J., … Shead, D. A. (2018). NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(1), 11–20. -
Clinical implications of gastrointestinal symptoms in systemic amyloidosis
Yen, T., Chen, F. W., Witteles, R. M., Liedtke, M., & Nguyen, L. A. (2018). Clinical implications of gastrointestinal symptoms in systemic amyloidosis. NEUROGASTROENTEROLOGY AND MOTILITY, 30(4), e13229. -
NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response
Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., … Gertz, M. A. (2017). NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response. ONCOLOGY RESEARCH AND TREATMENT, 40, 34–35. -
NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY
Gertz, M., Comenzo, R. L., Landau, H., Sanchorawala, Weiss, B. M., Zonder, J. A., … Liedtke, M. (2017). NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 22(3), 289–90. -
Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE
Jabbour, E. J., DeAngelo, D. J., Stelljes, M., Stock, W., Liedtke, M., Gokbuget, N., … Kantarjian, H. M. (2018). Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE. CANCER, 124(8), 1722–32. -
Novel therapeutic approaches for AL amyloid
Liedtke, M. (2017). Novel therapeutic approaches for AL amyloid. ONCOLOGY RESEARCH AND TREATMENT, 40, 194. -
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
DeAngelo, D. J., Stock, W., Stein, A. S., Shustov, A., Liedtke, M., Schiffer, C. A., … Advani, A. S. (2017). Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. BLOOD ADVANCES, 1(15), 1167–80. -
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., & Liedtke, M. (2017). Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. BLOOD, 130(7), 900–902. -
Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response
Saygin, C., Papadantonakis, N., Cassaday, R. D., Liedtke, M., Fischer, K., Dunn, T., … Advani, A. S. (2018). Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. LEUKEMIA & LYMPHOMA, 59(2), 363–71. -
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Dinner, S., Dunn, T. J., Price, E., Coutré, S. E., Gotlib, J., Berube, C., … Liedtke, M. (2018). A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. International Journal of Hematology. -
Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients.
Yurkiewicz, I. R., Simon, P., Liedtke, M., Dahl, G., & Dunn, T. (2018). Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients. Journal of Adolescent and Young Adult Oncology. -
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma
Richardson, P. G., Hofmeister, C. C., Rosenbaum, C. A., Htut, M., Vesole, D. H., Berdeja, J. G., … Baz, R. (2018). Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. BRITISH JOURNAL OF HAEMATOLOGY, 182(2), 231–44. -
Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Yurkiewicz, I. R., Muffly, L., & Liedtke, M. (2018). Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. DRUG DESIGN DEVELOPMENT AND THERAPY, 12, 2293–2300. -
Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis
Yen, T., Chen, F., Witteles, R., Liedtke, M., & Nguyen, L. A. (2017). Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis. AMERICAN JOURNAL OF GASTROENTEROLOGY. NATURE PUBLISHING GROUP. -
Antibody-based therapies in patients with acute lymphoblastic leukemia.
Dinner, S., & Liedtke, M. (2018). Antibody-based therapies in patients with acute lymphoblastic leukemia. Hematology. American Society of Hematology. Education Program, 2018(1), 9–15. -
Daratumumab vs. pomalidomide for the treatment of relapsed/refractory multiple myeloma: a cost-effectiveness analysis.
Gong, C. L., Studdert, A. L., & Liedtke, M. (2018). Daratumumab vs. pomalidomide for the treatment of relapsed/refractory multiple myeloma: a cost-effectiveness analysis. American Journal of Hematology. -
Grading cardiac response in AL amyloidosis: implications for relapse and survival.
Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., … Liedtke, M. (2018). Grading cardiac response in AL amyloidosis: implications for relapse and survival. British Journal of Haematology. -
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
Jabbour, E., Advani, A. S., Stelljes, M., Stock, W., Liedtke, M., Gokbuget, N., … Kantarjian, H. M. (2019). Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. American Journal of Hematology. -
A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph plus ALL): Final Results of Alliance/CALGB Study 10701
Wieduwilt, M. J., Yin, J., Wetzler, M., Uy, G. L., Powell, B. L., Kolitz, J. E., … Larson, R. A. (2018). A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph plus ALL): Final Results of Alliance/CALGB Study 10701. BLOOD, 132. -
Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse
Aleshin, A., Durruthy-Durruthy, R., Corces, M. R., Stafford, M., Liedtke, M., Medeiros, B. C., … Majeti, R. (2018). Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse. BLOOD, 132. -
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., … Costa, L. J. (2019). Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. -
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., … Advani, A. S. (2019). Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. -
Contemporary Outcomes in Patients with Cardiac Amyloidosis Undergoing Heart Transplantation
Alexander, K., Barrett, C., Dobos, K., Cheng, P., Liao, R., Wheeler, M., … Witteles, R. (2019). Contemporary Outcomes in Patients with Cardiac Amyloidosis Undergoing Heart Transplantation. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 38(4), S215. -
Therapy-related myeloid neoplasms after treatment for plasma-cell disorders.
Chung, A., & Liedtke, M. (2019). Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. Best Practice & Research. Clinical Haematology, 32(1), 54–64. -
Therapy-related myeloid neoplasms after treatment for plasma-cell disorders
Chung, A., & Liedtke, M. (2019). Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 32(1), 54–64. -
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
Stock, W., Luger, S. M., Advani, A. S., Yin, J., Harvey, R. C., Mullighan, C. G., … Larson, R. A. (2019). A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. BLOOD, 133(14), 1548–59. -
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., … Kochenderfer, J. N. (2019). Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. NEW ENGLAND JOURNAL OF MEDICINE, 380(18), 1726–37. -
B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma
Eckhert, E., Hewitt, R., & Liedtke, M. (2019). B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma. IMMUNOTHERAPY, 11(9), 801–11. -
Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients
Yurkiewicz, I. R., Simon, P., Liedtke, M., Dahl, G., & Dunn, T. (2018). Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients. JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, 7(5), 579–83. -
Grading cardiac response in AL amyloidosis: implications for relapse and survival
Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., … Liedtke, M. (2019). Grading cardiac response in AL amyloidosis: implications for relapse and survival. BRITISH JOURNAL OF HAEMATOLOGY, 186(1), 144–46. -
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Goekbuget, N., … Advani, A. S. (2019). Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. CANCER, 125(14), 2474–87. -
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., … Costa, L. J. (2019). Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. LEUKEMIA, 33(9), 2266–75. -
Outcome of relapsed or refractory acute lymphoblastic leukemia patients with extramedullary disease or lymphoblastic lymphoma receiving inotuzumab ozogamicin or standard care in the INO-VATE trial
Marks, D. I., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., … Kantarjian, H. (2019). Outcome of relapsed or refractory acute lymphoblastic leukemia patients with extramedullary disease or lymphoblastic lymphoma receiving inotuzumab ozogamicin or standard care in the INO-VATE trial. BONE MARROW TRANSPLANTATION, 54, 149–51. -
A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.
Barrett, C. D., Dobos, K., Liedtke, M., Tuzovic, M., Haddad, F., Kobayashi, Y., … Witteles, R. M. (2019). A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis. JACC. Heart Failure. -
Single-cell mutational profiling of paired AML samples at diagnosis, remission and relapse: Implications for therapeutic resistance and MRD detection
Aleshin, A., Durruthy-Durruthy, R., Corces, R., Liedtke, M., Eastburn, D., & Majeti, R. (2019). Single-cell mutational profiling of paired AML samples at diagnosis, remission and relapse: Implications for therapeutic resistance and MRD detection. CANCER RESEARCH, 79(13). -
Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines
Kumar, S. K., Callender, N. S., Hillengass, J., Liedtke, M., Baljevic, M., Campagnaro, E., … Kumar, R. (2019). Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(10), 1155–65. -
Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM)
Cornell, R., Parameswaran, H., Tang, S., Barnstead, A., Biran, N., Callander, N., … Costa, L. (2019). Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19(10), E115–E116. -
Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia.
Granja, J. M., Klemm, S., McGinnis, L. M., Kathiria, A. S., Mezger, A., Corces, M. R., … Greenleaf, W. J. (2019). Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia. Nature Biotechnology. -
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour, E., Gokbuget, N., Advani, A., Stelljes, M., Stock, W., Liedtke, M., … Kantarjian, H. (2019). Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leukemia Research, 88, 106283. -
Cutaneous plasmablastic plasmacytoma.
Chung, A., & Liedtke, M. (2019). Cutaneous plasmablastic plasmacytoma. Blood, 134(23), 2116. -
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.
Saygin, C., Kishtagari, A., Cassaday, R. D., Reizine, N., Yurkiewicz, I., Liedtke, M., … Advani, A. S. (2019). Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Advances, 3(24), 4228–37. -
Organ responses with daratumumab therapy in previously treated AL amyloidosis.
Chung, A., Kaufman, G. P., Sidana, S., Eckhert, E., Schrier, S. L., Lafayette, R. A., … Liedtke, M. (2020). Organ responses with daratumumab therapy in previously treated AL amyloidosis. Blood Advances, 4(3), 458–66. -
Gene Signatures to Distinguish Amyloid Cardiomyopathy Risk in Multiple Myeloma Patients
Jha, A., Morgado, I., Lee, D. J., Alexander, K., Tsai, C.-Y., Schimmel, K., … Dangwal, S. (2019). Gene Signatures to Distinguish Amyloid Cardiomyopathy Risk in Multiple Myeloma Patients. CIRCULATION RESEARCH, 125. -
Single-cell mutational profiling enhances the clinical evaluation of AML MRD.
Ediriwickrema, A., Aleshin, A., Reiter, J. G., Corces, M. R., Köhnke, T., Stafford, M., … Majeti, R. (2020). Single-cell mutational profiling enhances the clinical evaluation of AML MRD. Blood Advances, 4(5), 943–52. -
Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience
Badar, T., Advani, A. S., Liedtke, M., Arslan, S., Khan, M. A., Aldoss, I., … Atallah, E. (2020). Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC. -
Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.
Badar, T., Szabo, A., Wadleigh, M., Liedtke, M., Arslan, S., Siebenaller, C., … Atallah, E. (2020). Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. Clinical Lymphoma, Myeloma & Leukemia. -
Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation.
Barrett, C. D., Alexander, K. M., Zhao, H., Haddad, F., Cheng, P., Liao, R., … Witteles, R. M. (2020). Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. JACC. Heart Failure. -
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab.
Badar, T., Szabo, A., Advani, A., Wadleigh, M., Arslan, S., Khan, M. A., … Atallah, E. (2020). Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Advances, 4(10), 2308–16. -
Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
Lemieux, C., Muffly, L. S., Rezvani, A., Lowsky, R., Iberri, D. J., Craig, J. K., … Sidana, S. (2020). Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation. -
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
DeAngelo, D. J., Advani, A. S., Marks, D. I., Stelljes, M., Liedtke, M., Stock, W., … O'Brien, S. (2020). Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer Journal, 10(8), 81. -
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone versus standard of care in MAMMOTH.
Cornell, R., Hari, P., Tang, S., Biran, N., Callander, N., Chari, A., … Costa, L. (2020). Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone versus standard of care in MAMMOTH. American Journal of Hematology. -
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
Stock, W., Martinelli, G., Stelljes, M., DeAngelo, D. J., Gokbuget, N., Advani, A. S., … Kantarjian, H. M. (2020). Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia. Cancer. -
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Badar, T., Szabo, A., Dinner, S., Liedtke, M., Burkart, M., Shallis, R. M., … Atallah, E. (2020). Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. -
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L., Baljevic, M., Campagnaro, E., … Kumar, R. (2020). Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 18(12), 1685–1717. -
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
Premkumar, V. J., Lentzsch, S., Pan, S., Bhutani, D., Richter, J., Jagannath, S., … Kapoor, P. (2021). Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer Journal, 11(1), 10. -
Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML.
Ladha, A., Hui, G., Cheung, E., Berube, C., Coutre, S. E., Gotlib, J., … Mannis, G. N. (2021). Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML. Leukemia & Lymphoma, 1–6. -
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.
Advani, A. S., Larsen, E., Laumann, K., Luger, S. M., Liedtke, M., Devidas, M., … Stock, W. (2021). Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Advances, 5(2), 504–12. -
AL Amyloidosis for the Cardiologist and Oncologist Epidemiology, Diagnosis, and Management
Witteles, R. M., & Liedtke, M. (2019). AL Amyloidosis for the Cardiologist and Oncologist Epidemiology, Diagnosis, and Management. JACC: CARDIOONCOLOGY, 1(1), 117–30. -
Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Rezvani, A., Lowsky, R., Frank, M. J., … Sidana, S. (2020). Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).
Tam, E. L., Iberri, D. J., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M. J., … Sidana, S. (2020). Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Avoiding Catastrophe: Understanding Free Light Chain Testing in the Evaluation of ATTR Amyloidosis.
Witteles, R. M., & Liedtke, M. (2021). Avoiding Catastrophe: Understanding Free Light Chain Testing in the Evaluation of ATTR Amyloidosis. Circulation. Heart Failure, CIRCHEARTFAILURE120008225. -
Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data.
Badar, T., Szabo, A., Litzow, M., Burkart, M., Yurkiewicz, I., Dinner, S., … Atallah, E. (2021). Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplantation. -
Antibody-based therapies in patients with acute lymphoblastic leukemia
Dinner, S., & Liedtke, M. (2018). Antibody-based therapies in patients with acute lymphoblastic leukemia. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 9–15. -
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., … Sidana, S. (2021). Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation. -
Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography.
Matsumiya, W., Karaca, I., Ghoraba, H., Akhavanrezayat, A., Mobasserian, A., Hassan, M., … Nguyen, Q. D. (2021). Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography. American Journal of Ophthalmology Case Reports, 23, 101133. -
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., … Miklos, D. B. (2021). Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Advances, 5(16), 3147–3151. -
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
Ramasamy, K., Nooka, A., Quach, H., Htut, M., Popat, R., Liedtke, M., … Cho, H. J. (2021). A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma. Blood Cancer Journal, 11(9), 149. -
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL.
Wieduwilt, M. J., Yin, J., Wetzler, M., Uy, G. L., Powell, B. L., Kolitz, J. E., … Larson, R. A. (2021). Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. Blood Advances. -
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Brown, P. A., Shah, B., Advani, A., Aoun, P., Boyer, M. W., Burke, P. W., … Campbell, M. (2021). Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 19(9), 1079–1109. -
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma
Paul, B., Liedtke, M., Monge, J., Chaudhry, M., Rifkin, R., Gandhi, M., … Usmani, S. (2021). A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma. AMERICAN JOURNAL OF HEMATOLOGY. WILEY. -
Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.
Bal, S., Malek, E., Kansagra, A., Usmani, S. Z., Vij, R., Godby, K. N., … Costa, L. J. (2021). Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia. -
Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403.
Raychaudhuri, S., Yurkiewicz, I., Mannis, G. N., Medeiros, B. C., Coutre, S. E., Muffly, L. S., & Liedtke, M. (2021). Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma
Malek, E., Kansagra, A., Costa, L., Usmani, S. Z., Vij, R., Kumar, S., … Liedtke, M. (2021). Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. -
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.
Costa, L. J., Lin, Y., Cornell, R. F., Martin, T., Chhabra, S., Usmani, S. Z., … Hari, P. (2021). Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma & Leukemia. -
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., … Munshi, N. C. (2022). Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. The New England Journal of Medicine. -
Multiple Myeloma, Version 3.2022 Featured Updates to the NCCN Guidelines
Callander, N. S., Baljevic, M., Adekola, K., Anderson, L. D., Campagnaro, E., Castillo, J. J., … Kumar, S. K. (2022). Multiple Myeloma, Version 3.2022 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 20(1), 9–19. -
Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma.
Miao, Y. R., Thakkar, K., Cenik, C., Jiang, D., Mizuno, K., Jia, C., … Giaccia, A. J. (2022). Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma. The Journal of Experimental Medicine, 219(9). -
Case Report: Mature Plasmacytoid Dendritic Cell Proliferation Associated With a Lymphoid Neoplasm.
Fei, F., Liedtke, M., & Silva, O. (2022). Case Report: Mature Plasmacytoid Dendritic Cell Proliferation Associated With a Lymphoid Neoplasm. Frontiers in Oncology, 12, 903113. -
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.
Muchtar, E., Dispenzieri, A., Wisniowski, B., Palladini, G., Milani, P., Merlini, G., … Gertz, M. A. (2022). Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2200643. -
The impact of early PEG-asparaginase discontinuation in young adults with ALL: A post hoc analysis of the C10403 study.
Aldoss, I., Yin, J., Wall, A., Mrozek, K., Liedtke, M., Claxton, D., … Luger, S. M. (2022). The impact of early PEG-asparaginase discontinuation in young adults with ALL: A post hoc analysis of the C10403 study. Blood Advances. -
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases.
Dispenzieri, A., Zonder, J., Hoffman, J., Wong, S. W., Liedtke, M., Abonour, R., … Nair, S. (2022). Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases. Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis, 1–8. -
AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review.
Wechalekar, A. D., Fontana, M., Quarta, C. C., & Liedtke, M. (2022). AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review. JACC. CardioOncology, 4(4), 427–441. -
Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias.
Testa, S., Kumar, J., Goodell, A. J., Zehnder, J. L., Alexander, K. M., Sidana, S., … Liedtke, M. (2022). Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias. Seminars in Oncology. -
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., … Kumar, S. K. (2023). Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nature Medicine. -
Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Gertz, M. A., Cohen, A. D., Comenzo, R. L., Kastritis, E., Landau, H. J., Libby, E. N., … Merlini, G. (2023). Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood. -
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.
Lin, Y., Raje, N. S., Berdeja, J. G., Siegel, D. S., Jagannath, S., Madduri, D., … Kochenderfer, J. N. (2023). Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nature Medicine. -
Implementation of a Pilot Clinic for Pediatric to Adult Cancer Survivorship Transitions.
Jin, A. H., Simon, P. J., Clayton, A., Benedict, C., Liedtke, M., Muffly, L., … Smith, S. M. (2023). Implementation of a Pilot Clinic for Pediatric to Adult Cancer Survivorship Transitions. Journal of Adolescent and Young Adult Oncology.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma »
- Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab »
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis »
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis »
- A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets »
- A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia »
- Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma »
- Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) »
- Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia »
- Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma »
- Longterm Follow-up of Subjects Treated With bb2121 »
- Study of bb2121 in Multiple Myeloma »
- Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia »
Practice Locations
Hematologic Cancer Program Palo Alto, CA
Palo Alto, CA
Hematologic Cancer Program
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Amyloid Center Stanford, CA
Stanford, CA
Amyloid Center
300 Pasteur Drive , 2nd Floor, Room A260
Stanford , CA 94305
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(350 reviews)
She provides excellent care and follow up. She is extremely caring and kind. I feel fortunate to have her on my care team
I appreciate her bedside manner and willingness to listen.
She is great. She has provided me with valuable and informative information regarding my health issue. She shows geniune care and concern for my health and well-beng.
She is great
Great doctor!
Dr. Leidtke was very compassionate. I truly felt that she honestly and seriously cared about me. She put me at ease. And I began to finally comprehend that my health condition will improve and that I will live a long and beautiful life.
She is excellent all around!
She is very sharp, kind, and responsive. Basically perfect.
Dr. Liedtke is an incredible asset to Stanford Health. I always look forward to speaking with her, and I have the utmost confidence in her expertise and the genuine concern she shows for my health and well being.
Excellent doctor
Doctor Liedtke is the finest Physician provider that I have ever been blessed with in my 72 years of life. A life which she personally saved. :)
She is the Best!!
I greatly appreciate all the medical care and support I have gotten from Michaela Liedtke.
She's terrific. Responsive, knowledgeable and friendly.
She’s amazing!
She was highly informative, personable, gracious. The visit was most helpful to me in making a vital health care treatment decision. She only wished that she had known how urgent our request to hear her advice was so that we did not have to wait four months for this appointment.
What a compassionate, caring doctor. She was so lovely.
She is a very good doctor and always tries to be helpful
Good to talk to. Good communicator. Answers all questions.
She is the most informed, professional, and caring doctor we have ever encountered.
Dr Liedke was excellent in all respects.
Dr. Liedtke has been extremely professional and caring. She is able to provide clear, detailed answers to any question I have had and is patient to explain things in a way I can understand.
Excellent physician! Very kind, caring and very knowledgeable.
Extremely thankful to have her as my physician
Dr Liedtke is awesome. I appreciate her thoughtful and clear answers to my questions.
As always excellent visit with Dr, Liedtke
It is reassuring to have Dr. Liedtke review all by blood/urine tests. I can rest assured that I'm getting the best review of the results. Her clear & concise presentation of the data is extremely helpful. Also - her close contacts with my other Stanford doctors is great.
Very good doctor
Dr Liedtke is very knowledgeable and is keeping me healthy. She is very patient and good listener. Thank you
She is always kind and helpful. She takes the time needed to fully explain any questions asked. You never feel rushed.
I would recommend her to anyone! She is a great doctor!
Excellent, caring physician.
She is superb. Stanford is lucky to have such a knowledgable and friendly physician. She has an excellent bedside manner.
Dr Liedtke is an excellent doctor, very knowledgeable, very compassionate, and very patient in answering all my questions clearly and in full.
I'm very happy she's my doctor.
Doctor Liedtke is an amazing physician with a smile and the personality to make patients comfortable. Dot is very obvious that she is superior in her field.
I am extremely happy to have Doctor Liedtke on the team of providers that is helping with my health issues.
Dr. Liedtke is an excellent doctor who thoroughly listens to and answers all of my questions.
She is great and explained my options clearly
Dr Liedtke is a great communicator and a very knowledgeable doctor. She is open to all my questions and answers them honestly and speedily. I feel taken care of and I know I am in the best hands I possibly can be. I am grateful for being a patient of. dr Liedtke!
It is a great pleasure and very reassuring to have Dr Liedtke as my doctor. She is very detail oriented and has excellent way of explaining the next steps and reasons to the patient.
Excellent Dr.
Easy to fallow
Thank you
Knowledgeable and attentive.
A plus in every way! Expertise, communication style, supporting team…..fantastic!
Dr. Michaela Liedtke is an excellent provider. She is very accomplished, knowledgeable, compassionate, a great listener. She listens to my concerns and questions and provides her professional, experienced input regarding my medical issues.
Dr. Liedtke has been my hematology specialist for the last six years, taking care of my amyloidosis condition. She has a pleasant attitude and is very attentive to my needs and concerns. I really appreciate her care and wish her the best in her research and practice.
Dr. Liedtke is very knowledgeable and clearly relates important information in an understandable way for the patient and family to process. She is attentive to questions and provides thorough responses in a way that is thoughtful to the patient's particular needs.
She’s wonderful!
Dr. Liedtke is very professional. She gives details of my condition and explain why and what can happen in a certain situation, or why and how. Very patient and understanding .
Excellent doctor. Very through and also very easy to talk to.
She is wonderful
She's just fabulous!
She is a very knowledgeable, articulate, and caring physician.
Dr Liedtke was thorough, explained my medical condition in terms I could understand and made me feel like she is genuinely concerned about my medical condition.
She's the best! And Dr. Eckhert was also excellent.
She is extremely kind and compassionate.
Excellent Doctor. Liked her Fellow Dr too. He was very personable and nice.
Dr Lidtke is the best. She is keeping me alive and researching options for my cure!
I always feel fortunate to speak with her because she always answers my questions with clarity. She provides me with confidence as I deal with this cancer.
I love her! She takes her time and answers all my questions. She is compassionate and understanding.
Dr Michaela Liedtke is very good with her patient. She listen to you and answer all your concerns and questions. Before you end the visit she makes sure to let you know she is available at anytime. Great quality’s for a physician.
Dr. Liedtke is the best doctor I've ever had. She's extremely caring, empathetic, and smart.
Dr. Liedtke is wonderful: competent, informative, supportive. I have complete trust in her.
Dr. Michaela Leidtke is very kind and knowledgeable and very very helpful.
She is great
Shahram Hakim-Baba
I have complete confidence in Dr Liedtke. She is always totally aware of my specific case and accurately responds to tests results as well as my concerns.
She is very professional. She lets and answer all your questions.
She’s the most caring doctor I’ve ever had. She’s professional yet shows her caring heart and compassion for her patients.
I am very grateful to have Dr Liedtke as my Oncologist. She is as knowledgeable as she is compassionate. She is a true partner my heath care helping me to navigate through my health challenges..
Thanks
I appreciate her knowledge and willingness to listen.
Dr. Liedtke is an excellent doctor in every way possible. She has provided me with very helpful information and excellent care for several years.
Dr. Liedtke is an exceptional provider. She is an expert professional in her field. She is an excellent listener, compassionate, always willing to assist in matters and allows her patients to have input into the decision making.
She is one of the sweetest doctor's I've ever had the pleasure to meet. Her expertise is apparent in her care.
Excellent. I feel lucky to have her as one of my doctors.
Dr. Liedtke is highly competent and an excellent communicator.
She is an excellent doctor.
Dr. Liedtke is an outstanding doctor and has provided the best treatment I could have hoped for. I am extremely grateful for her knowledge, insight, and compassion.
Dr. Liedtke is very kind and compassionate.
Dr. Liedtke is excellent.
Dr Liedtke was wonderful. Thorough explanation!
great physician
She is an excellent doctor and I and my family are very fortunate to have her take care of me. She is the best doctor one can have.
Dr Liedtke is very personable. She is very open to questions. She is incredibly knowledgeable. I feel very grateful that she is my doctor. I know I am in good hands.
Patient, thorough, open to any questions. (current or in the future). Excellent
She is not only a very competent Doctor but as well has great bed side manners. I am very happy to have.her as my Doctor.
She is extremely personable and very pleasant person. After visit we feel extremely happy and we wish there are more doctors like her. I believe most of the pain go away by doctor’s attitude towards their patients and Dr. Liedtke has that personality. God bless her.
Very Professional and knowledgeable
She is one of the most calm & compassionate Drs. I’ve dealt wit and I also work in medical practice that deal with many Drs.!
Best oncologist who I have completely trusted to manage my amyloidosis treatments.
Dr. Liedtke is excellent. She is thorough and takes the amount of time that is necessary. She's totally engaged during the visit.
Dr Liedtke Is a brilliant clinician and a caring empathetic physician . I am grateful she is my doctor.
Dr. Liedtke was impressive: knowledgeable, forthright, even-handed, caring.
She's great!!!
Stanford is fortunate to have a doctor as Dr. Liedtke on their staff, and I am fortunate to be her patient. She is kind and knowledgeable, down to Earth and I trust her completely.
Excellent and very supportive
Informative, methodical, Kind, considerate
She is thorough, knowledgeable and caring.
She listens well and answered my questions. She is also available in between visits if I have questions. Today her Fellow spoke with me first and then they spoke with me together. It was helpful to me and provided more information.
Shows interest, informative on test results. kept appointment on time
A superb doctor, competent and a good communicator.
She has been my Stanford Doctor since 2011 and I would not change her anytime in the future.
She is an excellent and supportive doctor.
She is expert in her field. Thank you again
She is the most wonderful doctor anyone could have. Very caring and concerned.
She was caring and very professional. We felt like she cared about our problems.
Dr. Liedtke is fantastic. She is a top expert in the field. As well she has great bedside manner, is accessible and happy to answer questions, very gracious, an excellent communicator. I am lucky to be in her care.
She is one of the best doctors I have ever known. Thoughtful, caring and knowledgeable. I would always recommend her to anyone who needs her expertise.
10 out of 10!
She responds promptly to emails, which I really appreciate. I feel blessed to have her as my Stanford doctor. She is great!
She is the best doctor. She answers all your questions and explains everything so that I can understand it. She is a great asset to Stanford. I am lucky and very grateful to have her as my doctor!
I deeply appreciate the time she takes to explain some of the details of proposed treatment plans.
Unbelievable excellent doctor
Very thoughtful….
Caring person
One on one bases!
I was very pleased with my appointment and would to have her assigned as my oncology doctor going forward.
She's fantastic -- thoughtful, caring, knowledgeable, communicative. Great in every way.
All good. Thanks.
I am lucky to have Dr. Liedtke to monitor my unique condition. I feel she is on the cutting edge and I will always receive the most up-to-date care available.
instills confidence
She is a very caring doctor who always provides answers to my questions and gives me hope for the future!
She's fantastic!!
Very caring, knowledgable Doctor. I trust her.
Michaela Liedtke is perhaps of the most competent, compassionate doctor I have ever worked with.
Awesome doctor would highly recommend her!
She is an excellent doctor who is supportive, compassionate and kind.
Thanks for a good video visit
Top notch in every way.
Dr. Michaela Liedtke is very knowledgeable, professional, compassionate.
She is a good listener and takes into account the patients concerns/input. She is a good medical advisor and includes the patient in care decisions.
Dr. Michaela Liedtke is very knowledgeable and very caring doctor.
I am happy to have her as my Sandford doctor.
She is wonderful -- brilliant and compassionate. Thank you!
Dr Liedtke always reassures me by answering all my questions.
This was my first visit with Dr Liedtke; I was concerned as it was shown as a 10 minute video visit. That did not prove to be a problem.
I felt that both Dr Liedtke & the resident Alanna did a good job of making me feel comfortable & answering my questions.
Dr Liedtke did not ask me to repeat her instruction or what I would do next, but that issue flowed naturally into the conversation and was clearly addressed.
I also felt that Dr Liedtke heard me when I expressed my extreme anxiety about needles & vaccinations; she acknowledged my concerns and I felt my concerns would be considered and addressed going forward.
That, and her comment & acknowledgement of my interest in gardening as my “happy place†,generated a feeling of comfort & rapport which I have almost never experienced with a doctor.
Overall I was very pleased with my first visit with Stanford & Dr Liedtke - and given the nature of my illness I am encouraged that I have a caring professional/partner going forward. I hope that feeling continues.
She cares. She is a fabulous physician
Clearly explanation.
friendly, knowledgeable, and can talk to us in usable language.
I feel like Dr. Liedtke is an excellent physician who understands my illness.
She is excellent doctor, not only skilled in her field but very caring and respectful. I am lucky to find her as my doctor
Dr. Liedtke is an outstanding physician. I am so blessed to have her on my team. She always makes me understand our goals and how to achieve them. Her knowledge of Amyloidosis is off the charts and her awareness of new drug therapy has given me hope. Thank you, to Stanford and the the powers that be, that brought her to this institution
Dr. Liedtke is a superb Physician provider and an exemplary person. . She literally save my life. I am grateful to be in her care.
Dr. Liedtke is an excellent doctor and has consistently given me helpful advice. I trust her completely to help manage my disease.
Great appointment. Great Doctor!!!
Just excellent in every way
I am very satisfied
Dr. Liedtke is extremely kind and very knowledgeable. She always asks about how I’m doing…generally. She explains everything thoroughly and I’m able to ask questions and get answers that I understand. We always come to a decision about follow up care that is amenable to both of us.
Great doctor!
So glad she is on my side.
Dr. Lidtke is the best physician I have ever seen when it comes to hematologic diseases. She explains everything. She gives options. She is kind, understanding, and listens to all of my concerns. I have not ever met a doctor that has her bedside manner.
She combines compassion with technical excellence and communicates very well.
Very professional but also seems very approachable and friendly.
I appreciated the visit with Dr. Liedtke very much. My concerns and questions were all answered thoroughly and her responses and explanations were thorough and clear. A specific treatment plan was put into place and I felt very satisfied with the visit.
Dr Liedtke,
is an amazing doctor not only from her medical skills as well her interpersonal skills. I immediately would recommend to her anyone with a similar situation like me. She really helped me to stabilize my condition over the last 3 years so I am in really good health by now again and I am very grateful for this.
She is great- an excellent motivator, explainer and physician. I am sooooo lucky to have her. She brightens my day!
Dr. Liedtke is an excellent doctor, she truly cares for her patients.
She is fabulous, well prepared and thoughtful about my options. I couldn’t ask for more from a Physicain.
Dr. Liedtke is professional and kind all in one. She is always very concerned about how I am feeling, it is always the first thing she asks. She takes all the time I need to formulate my thoughts and concerns and never seems in a hurry. We always end the call with a plan.
I can not say enough how wonderful she is! Would and have recommended her.
She is very open and thorough. She explained my options and told me what to expect very clearly.
I really trust all my Doctors at Stanford Health Care.
Dr.Liedtke came prepared for my visit, was patient in listening to me, provided all the answers, and made me feel extremely confident and comfortable that she will be there for me.
She's fantastic! She's responsive and anticipates possible issues. She is patient, comfortable and extremely easy to talk to about my health and any concerns that I might have.
She’s the best
Dr Liedtke is a lovely human being and a good doctor. However she is not clairevoyant and cannot guess what is happening to the patient's body without having physical contact.
Dr Liedtke is very patient and helpful in responding to my questions. I always feel like I am in very good hands and am genuinely cared for.
She is a wonderful doctor. Very thoughtful and extraordinarily bright. A pleasure to speak with.
Dr Liedtke was helpful, warm and very considerate and professional. She had immediate and clear answer for all my questions. It was a delight!
Excellent Doctor and appreciate her thorough care and listening to the issues and problems that I am currently dealing with.
Dr. Liedke is topnotch. Her medical knowledge and great way with people make her a treasure for Stanford Hospital.
She is so kind and very thorough
Easy to talk with, understanding, communicates well. Right on target with the tests and their interpretation.
She's fantastic -- so patient and thorough and pleasant and knowledgeable! Couldn't ask for more.
very caring
Dr. Liedtke was professional, caring and compassionate. I am very confident in her diagnosis and course of treatment. It was a great pleasure meeting her.
She is terrific
Great doctor. Easy to talk to and very professional. I would receive her to anyone.
She is very responsive to the patient's concerns.
I thought she was very thorough and very personable.
Wonderful doctor and person!
Dr Michaela Liedtke is a knowledgeable, kind and caring doctor. I feel fortunate to be under her care.
Dr. Liedke is an excellent doctor! She is thorough, knowledgeable, caring and a good communicator! She exceeds all of my needs and expectations.
Very happy with the visit
Dr. Took plenty of time to explain and answer all my questions, she was very patient, professional and knowledgeable. I could not say enough good things about
Excellent, kind, supportive, passionate patient care!!
Michaela Liedtke is a very personable person with great expertise in her field. She can explain things clearly and thoughtfully. She is knowledgeable with future research that is being done with regards to my rare disease and shares it with me.
Dr. Liedtke is excellent, very blessed to have her on my team
I think she is a wonderful doctor in partnering with me in caring for my health. Her approach to my care is a perfect fit for me because she truly listens and offers her expertise which I value greatly.
I had a very positive experience with Dr. Liedtke. She is professionally astute and personally engaging. I would definitely return to her if diagnosed with a hematological issue.
She is a wonderful, knowledgeable doctor. I am so glad we were able to see her again. I know my health is in the best hands with Dr. Liedtke.
She's the best!
Dr. Liedtke is a very knowledgeable and compassionate doctor. I am lucky to have her as my hematologist.
I liked her personally and professionally and found her suggested road forward consistent with what I had read on pubmed.org
She is always wonderful and I very much like talking with her to update my health situation.
She is a world expert, very accessible, great supporting team and has an outstanding personal style.
She was very approachable and knowledgeable. I really appreciated her.
Dr. Liedtke is an excellent provider.
Great doctor, very satisfied with the information provided, cleared my doubts.
I am very lucky to have Dr. Liedtke as my physician. She is very thorough, smart and personable. I feel secure under her care.
She is a wonderful, caring, and thorough doctor who I am very confident of
So we’ll informed and with an articulate way of sharing valuable information for me. I’m very grateful!
Dr, Liedtke. Is a blessing in my continued treatment for Amyloidosis. My family and I are so grateful to Dr. Liedtke and her team for
their expertise and continued care.
She's the best.
Very patient and able to provide useful information about my treatment questions.
She is above fabulous…seriously!
Awesome! Thank you so much ;)
Dr. Liedtke is an outstanding physician. She hears her patients and her focus is on patient quality of life. That is unique in today's world of medicine.
I can not think of anything further to say.
Wonderful doctor explains very well the options in treatment that you have
Dr. M. Liedtke is an OUTSTANDING Physician to whom I entrust my life.
The Stanford Amyloid Center is an incredible success. Thank you.
Wonderful person and doctor. she and her team are keeping me going with a very high quality of life.
Excellent visit
Very please with her and information she provided.
Very thorough and very personable
Dr. Liedtke is extremely knowledgeable and conscientious. She cares about me and has been prompt in her replies and treatment.
I feel very fortunate that she is my hematologist.
She's very patient-friendly, extremely knowledgeable, and very informative.
I appreciated her thoroughness in explaining the treatment protocol and side effects.
Dr Leidtke is the warmest most personable Dr I’ve ever met. Add to it her knowledge of myeloma and I cannot say enough praises for her care. She understands how hard this disease is and all the psychological factors with it. She makes me feel cared for, important and special. She wants to hear from me and she is so different than other Doctors I. The way she cares.
The reason I marked very likely vs extremely likely re recommending Michaela was because the visit was so short (a good thing) that it didn’t allow getting to know her better. I was very satisfied with her care.
She is fantastic. Very knowledgeable, helpful and polite.
Very informative and friendly and kind which was most appreciated
She is a great doctor, very thorough and communicates very well.
She's always great. Thank you, Dr Liedtke! (And Thomas was good too.)
I did on the previous page.
Dr. Liedtke made me feel at ease. She explained everything to me and my son was able to take notes for me. It was nice of her to say my family can reach out to her if they have any questions or concerns. I enjoyed chatting with her.
Dr. Liedtke is a compassionate physician who provides the needed clarity to a complex health situation. Greatly appreciate her as she has made all the difference to my accepting my diagnosis- because I know she will be there alongside. Thank you, Dr. Liedtke.
Very knowledgeable and helpful as well as genuine ly concerned about my health situation.
Excellent
She is great!
Dr. Liedtke is an excellent provider. She listens. She includes me in the decision making process for my care. She is an advocate for her patients.
However, it seems that physicians can be limited by what Stanford is able or willing to offer as options (i.e. specifically in regard to vaccine boosters for immunocompromised patients).
I appreciated her concern about my case. Ditto for Dr. Gupta.
Terrific Doctor and terrific video visit
Great doc/ great person!
Please see previous answer. She is excellent in all aspects her superior, up to date knowledge, clinical acumen, her sensitivity, a healer. I am very grateful.
Dr Liedke has a very approachable demeanor. She is very knowledgeable about the rare disease I have and shows concern as well as empathy knowing what I go through. She listens to what I have to say and evaluates according. I had very fond opinion of the care she give me.
Dr Liedtke was concerned and took the time to make sure all my concerns were addressed.
I have been a patient of Dr Liedtke’s for many years. She is always thoughtful and thorough. I place my trust in her for my current and future treatments of Multiple. Myeloma.
Dr. Liedtke is smart, personable, and compassionate - a rare combination.
She is wonderful.
Dr Liedtke is amazing, I feel very fortunate to have her as my oncologist
She is a wonderful doctor who I am extremely grateful for. She is extremely knowledgeable, caring and personable. I have full faith in her.
Very knowledgeable and compassionate.
Very thorough.
She seems to be a very nice and caring doctor. I felt very comfortable with her.
Very caring
Dr. Liedtke is personable, friendly and listens to me. She really cares about her patients!
Very supportive, provided update on the chemo I am taking.
Very nice and excellent physician.
I think she was great. She answered all my questions and did not try to answer what she didn't know. Instead she promised to look that question up and get back to me. I appreciate that.
Dr Liedtke is always very responsive and supportive.
Dr Liedtke was very empathic, highly knowledgable, thorough and great at communicating the complex issues surrounding my condition.
Good visit
Thanks
Excellent
I really appreciate Dr. Liedtke"s attention to every detail related to my health condition. She has a very pleasant attitude and I feel comfortable to discuss any issues and symptoms I may have with her. Her extensive knowledge and research about my condition makes me confident I am in good care. Thank you Dr. Liedtke.
She is very knowledgeable and I feel hopeful and reassured talking to her. I am optimistic that I shall continue to receive excellent care through her and Stanford.
Dr. Leidtke is a very good in taking care of my illness.
She is one of the best doctors I’ve every dealt with and since my case is rare- I’ve seen many Drs! Cannot say enough about her calm compassionate demeanor- after many different and some alarming diagnosis- she seems to understand the complexities of my situation with her knowledge and made me have hope for the first time in awhile!!
Dr. Liedtke is an outstanding doctor. She is aware of your medical condition and gives advice accordingly to needs.
I would highly recommend her for help.
See prior comment. She is awesome!
I really like her demeanor, enthusiasm and attitude towards my case and well-being. She will be in touch with my oncologist and is looking at doing the stem cell transplant treatment prior to my mastectomy; a different approach than what Kaiser had been considering for the last year. She is also surprised that I did not have a primary breast cancer oncologist assigned to me while working concurrent with the multiple myeloma/hematology oncologist. This makes sense to me although all the oncologist are part of the tumor board.
She was very friendly and helpful
Allowed me to ask questions & answered completely.
Dr. Liedtke is absolutely the best doctor and extremely knowledgeable. I needed a second opinion when the doctors at UCLA could not determine what was wrong with me. I did an internet search and found Stanford had the specialty department and the doctors I needed. I cannot say enough about Dr. Liedtke and she is a true hero in my book.
Highly competent, compassionate, caring and is a very nice person. Dr. Liedtke is patient and explains things very clearly. If there was an issue I would have complete confidence that it would be properly handled. It is enjoyable to work with her. Just outstanding in every way from my perspective. I am grateful to be in her care. Wow!
I appreciate how Dr. Liedtke listens to all my concerns and takes the time to answer all my questions.
Dr. Liedtke is a superstar physician.
Love Dr. Liedtke!
Love Dr. Liedtke!!
Great to have Dr. Liedtke for my care.
Dr. Liedtke has always been excellent to work with in addition, the attending fellow was quite good as well.
Everyone is so kind & helpful.
Dr. Liedtke is magnificent!
Being with Dr. Liedtke was a wonderful experience! She is everything a good doctor should be.
Dr. Michaela was so outstanding and I really appreciate the time she gave me. She the rare few that didn't rush me like I was a number.
Very good.
I had a very positive experience with all care providers, felt taken care of and given information for my understanding.
Dr. Liedtke is amazing; The resident fellows have been amazing too. Very professional and knowledgeable.
Live in N. Nevada. Love Dr. Liedtke. I wish we could see her every month!
I have often referred her to new people in my surgery group.
All Stanford docs I've had the last 15 yrs. have been excellent!
Dr. Liedtke was great!
Excellent.
All good.
Dr. Liedtke is excellent, the MD doing the initial consult was quite good as well.
I seen Dr. Greg Kaufman first the Dr. Liedtke. Thy were both amazing, I felt very comfortable with both. Dr. Liedtke was very nice and she made me feel like she really cared about me & my situation.
Found Dr. Liedtke and her asst. more than caring, knowledgeable and compassionate. I was so honored to have a doctor of her repute to work with me. She gave me hope, I'll never forget her and my experience with her.
Excellent experience.
Very good.
I was thoroughly pleased with Dr. Liedtke's explanation, I feel so blessed that she is my care provider.
Explained everything and answered all our questions and concerns. Very patient and understanding. A very caring person.
Dr. Liedtke and her resident fellow, Greg Kaufmann were amazing - so put me at ease - this was my first visit to Stanford and I was very impressed with both doctors.
Outstanding! Very thorough.
Every staff member seems to exert the same respect & courtesy to my wife & while we are there.
Dr. Michaela Liedtke is a great asset to your hospital, also Dr. Ronald Witteles. THANK YOU.
Dr. Liedke is a great doctor. Shows concern compassion in clinic encounter each and every visit.
She is always awesome never rushes.
We LOVE Dr. Liedtke.
She is excellent!
Dr. M. Liedtke, like Dr. LaPorte and Goldstein before her all excellent. Also, she works well with my local physician - coordinating my care.
My visit was a very good one.
Listened well to my questions/concerns. Explained thoroughly.
God bless you always I have had a very good experience on being treated by you.
Always very good.
They met all my expectations.
Reassurance on care needed given.
I was so impressed with Dr. Liedtke, her fellow, and everything else about Stanford that I've decided to use Stanford instead of UCSF.
She has taken the time to call me at home with suggestions on my care.
The best ever!!
Empathy very evident... reassuring experience.
I feel I have received outstanding care form Dr. Liedtke.
Good.
Good.
Excellent care and concern shown by Dr. Liedtke and Misty Mahaffey (NP) at my clinic appointment.
Dr. Liedtke is a very kind, caring, and a great doctor!
Love my oncologist, palliative. They are so kind.
All good.
They had me... with my questions that they were doing thanks.
All very good.
All very nice.
I have been very happy with the care I have received from Dr. Liedtke.
She is very respectful of my opinion. She is a very humble person, which is unusual in a MD.
Excellent svc.!
Dr. Liedtke is a fantastic doctor. The best I've ever seen. She explain everything to me and my family. It shows that she really cares -
Dr. Liedtke is the best - caring, informative and knowledgeable. I would recommend her to everybody.
Dr. Liedtke is genuinely caring - and competent - a combination that is exceptional.
She took the time to provide a detailed and clear explanation regarding my condition, the possibilities and her plan of action. Dr. Liedtke was EXCELLENT I have high confidence in this doctor.
Love Dr. Liedtke.
Dr. Liedtke is the best. She explains and shows concern for my health. I have complete confidence in her.
All very good.
Dr. Liedtke is wonderful - feel very fantastic to have her as my specialist.
We really love Dr. Liedtke. She is so caring and knowledgeable. We are lucky to have her as a provider. It is hard to find a doctor like her.
Outstanding physician for my particular disease.
Dr. Liedtke is a great communicator and inspires my confidence in her. I have a lot of questions and she listens and answers them all she is fully responsive to email communications and volunteered her work e-mail address.
Dr. Liedtke, PA, and NP were very knowledgeable. I could ask for any more professional staff to assist me.
I feel so fortunate to have Michaela Liedtke as my myeloma specialist. She answered questions, listens, is informative and caring - truly top notch - could not be in better hands.
Excellent doctor always concerned for me.
My experience with the nurses & doctors was great.
Good.
I feel very fortunate and grateful to be cared for by Dr Liedtke
I have the utmost confidence in Dr. Liedtke.
Nice and very kind.
Love everyone at Stanford they are kind and careing and very smart! I would not be alive if I didn't have Stanford to go to that's why I drive four hours to get there!
Dr Liedtke has been my doctor for eight years. She is very helpful, understanding, knowledgeable about my disease. My pain, my feelings and knows what treatment I need. She is the same the first time I saw her and until now. I am confident that she can cure me.
Excellent! Dr Liedtke is a great communicator. She always understands exactly what I'm asking and gives precise, understandable answers. She has never appeared rushed with me, giving all the time I need to ask questions. She is also very kind.
She was an awesome doctor. I was lucky and blessed to have her. She was so kind and considerate. A confident and gentle spirit and a great leader for her staff.
I have the highest degree of admiration and respect for Dr. Liedtke.
Dr. Liedtke is the best doctor I have ever had. I have seen many, but she by far is the very best. I am very blessed to have her.
Dr. Liedtke is very good at responding to messages with questions or concerns I might have between regular appointments. This is all done electronically through the website with no need for phone calls.
Fantastic.
Thank you Dr Liedtke
Always a good experience Dr. Liedtke is very caring and concerned; she always explains my condition in a way I understand. I really like Dr. Liedtke. She's a sweetheart!!!
Very pleased with my doctor - Excellent care - Dr. Liedtke.
Have been very impressed with Dr. Liedtke in all my dealings with her.
Dr. Liedtka listens to you and ask questions. She is understanding of your needs. Being a scrub nurse, I do not do things normally in my medical history. She understands that. She is great.
Impressive MD's!
No bad experience.
Dr. Liedtke is saving my life!
Dr. Liedtke had not seen us before, so she was a little surprised, but did a great job.
She's a sweetheart - We're very blessed to be in her care.
I am very confident with Dr. M Liedtke. Her name is outstanding.
Dr. Liedtke is excellent.
Good.
View More »
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- View referral status
- Access medical records